Outlook Therapeutics, Inc.

Snapshot

Outlook Therapeutics is a tiny biotech with a $35 million market cap that is burning through its cash reserves. The company reported $1.4 million in revenue for FY 2025 but lost $62.4 million in net income, driven by heavy research and development spending of $27.2 billion (likely a data error in the source, but clearly massive relative to revenue) and operating losses. It holds only $8.1 million in cash against $30.2 million in debt, leaving a cash runway of just 1.1 months at current burn rates.

What's Happening Right Now

• Thu 28th May '26 · Capital Raise: Outlook announced a $5.0 million registered direct offering to its largest stockholder, GMS Ventures, at $0.5855 per share to fund working capital.
• Tue 26th May '26 · FDA Appeal Win: The FDA granted Outlook's appeal regarding its lead drug LYTENAVA, reversing a previous rejection and clearing the path for a resubmission in June 2026.
• Fri 15th May '26 · Going Concern: The company reported substantial doubt about its ability to continue as a going concern, citing insufficient cash to fund operations for the next 12 months.